FTC’s $448m AbbVie win overturned

A US appeals court has cancelled a $448 million antitrust bill for AbbVie, in a blow for the US Federal Trade Commission (FTC).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AbbVie says bar for ‘sham litigation’ is too low

3 June 2021 AbbVie has again urged the US Supreme Court to save it from claims of filing sham litigation to block competition for testosterone treatment AndroGel.

Americas

Third Circuit under fire over FTC v AbbVie ruling

18 November 2020 The US Federal Trade Commission and AbbVie both want a federal appeals court to rehear a lawsuit accusing the drug company of quashing competition through sham patent litigation.

Big Pharma

Seventh Circuit urged to review AbbVie antitrust ruling

15 October 2020 Twenty US states, the US Federal Trade Commission, and consumer groups have asked the Seventh Circuit of the US Court of Appeals to reconsider a case claiming that AbbVie strived to prevent competition to its immunosuppressant drug, Humira.

More on this story

Americas

AbbVie says bar for ‘sham litigation’ is too low

3 June 2021 AbbVie has again urged the US Supreme Court to save it from claims of filing sham litigation to block competition for testosterone treatment AndroGel.

Americas

Third Circuit under fire over FTC v AbbVie ruling

18 November 2020 The US Federal Trade Commission and AbbVie both want a federal appeals court to rehear a lawsuit accusing the drug company of quashing competition through sham patent litigation.

Big Pharma

Seventh Circuit urged to review AbbVie antitrust ruling

More on this story

Americas

AbbVie says bar for ‘sham litigation’ is too low

3 June 2021 AbbVie has again urged the US Supreme Court to save it from claims of filing sham litigation to block competition for testosterone treatment AndroGel.

Americas

Third Circuit under fire over FTC v AbbVie ruling

18 November 2020 The US Federal Trade Commission and AbbVie both want a federal appeals court to rehear a lawsuit accusing the drug company of quashing competition through sham patent litigation.

Big Pharma

Seventh Circuit urged to review AbbVie antitrust ruling